Navigation Links
MEI Development Corporation and GE Healthcare Sign Strategic Agreement
Date:5/18/2009

GE's Sole-Source Agreement Spans MEI's Broad Solution Offerings

CORAL SPRINGS, Fla., May 18 /PRNewswire/ -- MEI Development Corporation (MEI), a subsidiary of The MEI Healthcare Group, announced today a strategic agreement with GE Healthcare (NYSE: GE), a leading provider of healthcare technology. The sole-source, strategic agreement offers GE Healthcare's customers the option of MEI's broad solutions, including development, financial, oncology, women's health and consulting services.

"Our partnership with MEI provides a single, seamless platform for a comprehensive imaging solution," said Bob White, Senior Vice President, GE Healthcare. "When customers are provided with a robust, scalable model under one platform, the quality and cost of healthcare delivery improves."

"Our agreement ensures that MEI will continue to provide physician and hospital clients with seamless access to GE's industry-leading technology, which is fundamental to delivering MEI's comprehensive solution portfolio," said Gordon Baltzer, President and CEO of The MEI Healthcare Group.

MEI Development Corporation provides turnkey solutions for physicians, outpatient facilities and hospitals that are interested in adding and updating imaging technology. MEI offers a unique array of services including determining project viability, creation and implementation of business planning, procurement of imaging equipment and complete project financing.

About MEI: The MEI Healthcare Group, LLC, headquartered in Coral Springs, Florida, is a healthcare strategy firm that works with physician groups and medical centers to provide turnkey healthcare solutions for imaging and radiation therapy services.

About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com

    CONTACT:
    Nick Wasmiller
    Seyferth & Associates Inc.
    1-800-435-9539
    wasmiller@seyferthpr.com


'/>"/>
SOURCE MEI Development Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin Receives 2009 Corporate Award for the Development of Kuvan
2. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
3. arc Thrift Stores to Honor Individuals and Businesses Who Support People With Developmental Disabilities
4. Oxygen Biotherapeutics, Inc. Signs Cooperative Research and Development Agreement With Naval Medical Research Center and Walter Reed Army Institute of Research
5. iJET Provides Additional Services in Response to Ongoing H1N1 Influenza A (Swine Flu) Developments
6. Recent developments at Burnham Institute for Medical Research, May 2009
7. VIDEO from Medialink and the Society of Interventional Radiology: Prostate and Kidney Cancer - New Life-Changing Developments
8. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
9. Cardium Reports on First Quarter 2009 Financial Results and Recent Developments
10. Children's Hospital Boston Advances Cutting-Edge Technologies with its New Technology Development Fund
11. Prematics Names S. Michael Ross Chief Medical Officer and Senior Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: